Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5625)
All Articles published online
|
Publishing Process of This Article
|
Dec 21, 2013 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19(47): 8822-8830 [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v19/i47/8822.htm |
| Number | Citing Articles |
| 1 |
Yuanyuan Liu, Vaishnavi Veeraraghavan, Monica Pinkerton, Jianjun Fu, Mark W. Douglas, Jacob George, Thomas Tu. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Frontiers in Microbiology 2021; 12 doi: 10.3389/fmicb.2021.665201
|
| 2 |
Yinghua Zhang, Chuanfang Wang, Hui Li, Yuanyuan Ding. Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Medicine 2019; 98(3): e13929 doi: 10.1097/MD.0000000000013929
|
| 3 |
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. Journal of Clinical and Experimental Hepatology 2020; 10(1): 43 doi: 10.1016/j.jceh.2019.09.007
|
| 4 |
George V. Papatheodoridis, Ramazan Idilman, George N. Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Onur Keskın, Nikolaos Gatselis, Bettina E. Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017; 66(5): 1444 doi: 10.1002/hep.29320
|
| 5 |
Dan-Hong Yang, Wei-Ping Wang, Qiang Zhang, Hong-Ying Pan, Yi-Cheng Huang, Jia-Jie Zhang. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World Journal of Gastroenterology 2021; 27(17): 2025-2038 doi: 10.3748/wjg.v27.i17.2025
|
| 6 |
Rukaiya Bashir Hamidu, Divya M. Chalikonda, Hie-Won Hann. Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series. Vaccines 2021; 9(8): 838 doi: 10.3390/vaccines9080838
|
| 7 |
Kung-Hao Liang, Chao-Wei Hsu, Ming-Ling Chang, Yi-Cheng Chen, Ming-Wei Lai, Chau-Ting Yeh. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. Journal of Infectious Diseases 2016; 213(6): 966 doi: 10.1093/infdis/jiv547
|
| 8 |
Yong-Wei Li, Feng-Cai Yang, Hui-Qiong Lu, Jiong-Shan Zhang. Hepatocellular carcinoma and hepatitis B surface protein. World Journal of Gastroenterology 2016; 22(6): 1943-1952 doi: 10.3748/wjg.v22.i6.1943
|
| 9 |
Nevin Varghese, Amry Majeed, Suraj Nyalakonda, Tina Boortalary, Dina Halegoua-DeMarzio, Hie-Won Hann. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cancers 2024; 16(4): 777 doi: 10.3390/cancers16040777
|
| 10 |
Evangelos Cholongitas, Ioannis Goulis, Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou, Evangelos Akriviadis. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transplant International 2014; 27(10): 1022 doi: 10.1111/tri.12370
|
| 11 |
Alkistis Papatheodoridi, Antonios Chatzigeorgiou, Lampros Chrysavgis, Panagiotis Lembessis, Alessandro Loglio, Floriana Facchetti, Evangelos Cholongitas, Michael Koutsilieris, Pietro Lampertico, George Papatheodoridis. Circulating cell‐free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. Journal of Viral Hepatitis 2021; 28(3): 464 doi: 10.1111/jvh.13446
|
| 12 |
Walid S. Ayoub, Paul Martin, Pietro Lampertico. Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?. Current Hepatology Reports 2015; 14(4): 279 doi: 10.1007/s11901-015-0279-1
|
| 13 |
Jiannis Vlachogiannakos, George V. Papatheodoridis. Hepatitis B: Who and when to treat?. Liver International 2018; 38(S1): 71 doi: 10.1111/liv.13631
|
| 14 |
Mi Na Kim, Seong Gyu Hwang, Kyu Sung Rim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Seung Up Kim. Validation of PAGE‐B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver International 2017; 37(12): 1788 doi: 10.1111/liv.13450
|
| 15 |
Lihu Gu, Qigu Yao, Zefeng Shen, Ying He, Derry Minyao Ng, Tong Yang, Bangsheng Chen, Ping Chen, Feiyan Mao, Qili Yu. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2020; 35(9): 1467 doi: 10.1111/jgh.15036
|
| 16 |
Jiannis Vlachogiannakos, George V. Papatheodoridis. Optimal therapy of chronic hepatitis B: how do I treat HBeAg‐positive patients?. Liver International 2015; 35(s1): 100 doi: 10.1111/liv.12719
|
| 17 |
Alberto Ferrarese, Alberto Zanetto, Martina Gambato, Ilaria Bortoluzzi, Elena Nadal, Giacomo Germani, Marco Senzolo, Patrizia Burra, Francesco Paolo Russo. Liver transplantation for viral hepatitis in 2015. World Journal of Gastroenterology 2016; 22(4): 1570-1581 doi: 10.3748/wjg.v22.i4.1570
|
| 18 |
思远 张. Research Progress on the Impact of Platelets on the Occurrence, Development, and Treatment of Liver Cancer. Advances in Clinical Medicine 2024; 14(03): 541 doi: 10.12677/ACM.2024.143736
|
| 19 |
George Papatheodoridis, George Dalekos, Vana Sypsa, Cihan Yurdaydin, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskin, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. Journal of Hepatology 2016; 64(4): 800 doi: 10.1016/j.jhep.2015.11.035
|
| 20 |
George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. Journal of Hepatology 2020; 73(5): 1037 doi: 10.1016/j.jhep.2020.06.011
|
| 21 |
Jiannis Vlachogiannakos, George V. Papatheodoridis. HBV: Do I treat my immunotolerant patients?. Liver International 2016; 36(S1): 93 doi: 10.1111/liv.12996
|
| 22 |
George V. Papatheodoridis, Vana Sypsa, George Dalekos, Cihan Yurdaydin, Florian van Boemmel, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Nikolaos Gatselis, Onur Keskın, Maria Lehretz, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology 2018; 68(6): 1129 doi: 10.1016/j.jhep.2018.01.031
|
| 23 |
George V. Papatheodoridis, George N. Dalekos, Cihan Yurdaydin, Maria Buti, John Goulis, Pauline Arends, Vana Sypsa, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskın, Savvoula Savvidou, Bettina E. Hansen, Christos Papaioannou, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. Journal of Hepatology 2015; 62(2): 363 doi: 10.1016/j.jhep.2014.08.045
|
| 24 |
Yuanyuan Sun, Yanhong Wang, Mengmeng Li, Kailiang Cheng, Xinyu Zhao, Yuan Zheng, Yan Liu, Shaoyuan Lei, Li Wang. Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis. BMJ Open 2018; 8(2): e020490 doi: 10.1136/bmjopen-2017-020490
|
| 25 |
Ji Hun Lee, Seung Kak Shin, Seong Hee Kang, Tae Hyung Kim, Hyung Joon Yim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Oh Sang Kwon, Soon Ho Um, Kwan Soo Byun. Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients. Journal of Clinical Medicine 2022; 11(22): 6613 doi: 10.3390/jcm11226613
|
| 26 |
Kwesi Z Tandoh, Osbourne Quaye. Genetic associations in chronic hepatitis B infection: toward developing polygenic risk scores. Future Microbiology 2022; 17(7): 541 doi: 10.2217/fmb-2021-0176
|
| 27 |
George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Reports 2021; 3(3): 100290 doi: 10.1016/j.jhepr.2021.100290
|
| 28 |
Margarita Papatheodoridi, George Papatheodoridis. Hepatitis B Virus and Liver Disease. 2021; : 267 doi: 10.1007/978-981-16-3615-8_12
|
| 29 |
Rukaiya Bashir Hamidu, Richard R. Hann, Hie-Won Hann. Chronicles of HBV and the Road to HBV Cure. Livers 2023; 3(2): 232 doi: 10.3390/livers3020015
|
| 30 |
Kyu Sik Jung, Seung Up Kim, Kijun Song, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Kwang‐Hyub Han. Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology 2015; 62(6): 1757 doi: 10.1002/hep.28115
|
| 31 |
Brianna J Shinn, Aaron Martin, Robert M Coben, Mitchell I Conn, Jorge Prieto, Howard Kroop, Anthony J DiMarino, Hie-Won Hann. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World Journal of Hepatology 2019; 11(1): 65-73 doi: 10.4254/wjh.v11.i1.65
|
| 32 |
George V. Papatheodoridis, Vana Sypsa, George N. Dalekos, Cihan Yurdaydin, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, Heng Chi, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Theodoros Voulgaris, Nikolaos Gatselis, Onur Keskin, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Ramazan Idilman, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology 2020; 72(6): 1088 doi: 10.1016/j.jhep.2020.01.007
|
| 33 |
Peipei Ren, Zhujun Cao, Ruidong Mo, Yuhan Liu, Lichang Chen, Ziqiang Li, Tianhui Zhou, Jie Lu, Yunye Liu, Qing Guo, Rong Chen, Huijuan Zhou, Xiaogang Xiang, Wei Cai, Hui Wang, Shisan Bao, Yumin Xu, Honglian Gui, Qing Xie. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opinion on Biological Therapy 2018; 18(10): 1085 doi: 10.1080/14712598.2018.1518423
|
| 34 |
Hye Won Lee, Sang Hoon Ahn. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World Journal of Gastroenterology 2016; 22(37): 8314-8321 doi: 10.3748/wjg.v22.i37.8314
|